Due to initial promising preclinical results, the first-in-human study of IDH inhibition began in 2013, treating patients with AML and IDH2 mutations with the mutant IDH2 inhibitor, enasidenib [29]. The gene discussed is IDH2; the disease is acute myeloid leukemia.